Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint
Abstract Background Targeting poly ADP-ribose polymerase (PARP) has been recently identified as a promising option against gastric cancer (GC). However, PARP inhibitors alone achieve limited efficacy. Combination strategies, especially with homologous recombination (HR) impairment, are of great hope...
Main Authors: | Xiaoting Lin, Dongshao Chen, Cheng Zhang, Xiaotian Zhang, Zhongwu Li, Bin Dong, Jing Gao, Lin Shen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-06-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13046-018-0790-7 |
Similar Items
-
Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations
by: Angela Flavia Serpico, et al.
Published: (2019-06-01) -
Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents
by: Federica Martorana, et al.
Published: (2022-02-01) -
Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment
by: Luisa Maresca, et al.
Published: (2022-04-01) -
Targeting DNA damage response as a potential therapeutic strategy for head and neck squamous cell carcinoma
by: Huimin Lei, et al.
Published: (2022-10-01) -
DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives
by: Öykü Gönül Geyik, et al.
Published: (2022-04-01)